Using MRI to Improve Surgery Selection for Pancreatic Cancer Patients
Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery (MAGIPAC): A Randomized Clinical Trial.
This study is testing whether using MRI along with CT scans can help doctors better decide if surgery is a good option for pancreatic cancer patients with possible liver spread.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | University of Aarhus Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Aalborg and 2 other locations) |
| Trial ID | NCT05428358 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the added value of magnetic resonance imaging (MRI) alongside computed tomography (CT) in the diagnostic assessment of pancreatic cancer patients. It will be a nationwide, prospective clinical trial focusing on the identification of liver metastases in patients deemed potentially resectable. By comparing the diagnostic outcomes of MRI and CT, the study seeks to enhance the decision-making process for surgical interventions in pancreatic cancer cases.
Who should consider this trial
Good fit: Ideal candidates include adults with locally resectable or borderline resectable pancreatic cancer who have no liver metastases as determined by CT.
Not a fit: Patients with metastatic disease, prior neoadjuvant treatment, or significant comorbidities that prevent surgery will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate surgical selection for pancreatic cancer patients, potentially improving patient outcomes.
How similar studies have performed: While the use of MRI in cancer diagnostics is established, this specific approach of combining MRI with CT for pancreatic cancer is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board * No liver metastases on CT * At least 18 years old and able to provide informed consent * Expected pancreatic ductal adenocarcinoma based on CT scan Exclusion criteria: * Metastatic disease * Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment * Comorbidity rendering major surgery unfeasible (inoperable) * No informed consent * Unable to undergo MRI (Kidney insufficiency (eGFR \< 60 ml/min/1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker) * Postoperative histology other than adenocarcinoma of pancreato-biliary origin. * MRI with liver-specific contrast performed during standard workup.
Where this trial is running
Aalborg and 2 other locations
- Aalborg University Hospital — Aalborg, Denmark (Recruiting)
- Aarhus University Hospital — Aarhus, Denmark (Recruiting)
- Rigshospitalet — Copenhagen, Denmark (Recruiting)
Study contacts
- Principal investigator: Jakob Kirkegård, MD, PhD — Aarhus University Hospital
- Study coordinator: Jakob Kirkegård, MD, PhD
- Email: jakob.kirkegaard@auh.rm.dk
- Phone: +4522900604
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.